Investors Who Have Lost Money in Their FibroGen Investment Should Contact Block & Leviton, Who Is Investigating Securities Fraud Claims Against FibroGenNewsfile Corp • 04/06/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEPRNewsWire • 03/24/21
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/16/21
FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another DelayInvestors Business Daily • 03/02/21
FibroGen's (FGEN) CEO Enrique Conterno on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
FibroGen (FGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/22/21
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2GlobeNewsWire • 12/22/20
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual MeetingGlobeNewsWire • 12/02/20
FibroGen's (FGEN) Evrenzo Approved in Japan for Another IndicationZacks Investment Research • 11/30/20
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on DialysisGlobeNewsWire • 11/27/20
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)GlobeNewsWire • 10/22/20
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 ReimaginedGlobeNewsWire • 10/14/20